Albuvirtide Lyophilized Composition With Acidic Buffer Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compositions of albuvirtide, an HIV-1 fusion inhibitor, face challenges in stability and manufacturing efficiency, requiring tailored pharmaceutical excipients to achieve optimal physical and pharmaceutical properties.
Innovation Solution
Development of liquid and lyophilized compositions of albuvirtide with defined buffer systems, organic solvent ratios, and pH ranges between 1.0 and 3.5, along with specific concentrations of albuvirtide and acidic buffers, enhancing stability and ease of administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional compositions of albuvirtide are used, then manufacturing can proceed with standard excipients, but stability and purity are compromised
Solution Approach 1:
The patent changes critical parameters of the composition including pH (adjusted to acidic range), buffer concentration, and excipient ratios to optimize stability. By systematically adjusting these parameters, the invention achieves improved albuvirtide stability while maintaining manufacturability through defined formulation guidelines.
Solution Approach 2:
The patent introduces specific buffer systems and excipients as intermediary substances that mediate between the albuvirtide and the formulation environment. These intermediaries protect the albuvirtide from degradation while allowing standard manufacturing processes to be used, thus resolving the contradiction between stability and ease of manufacture.
2Reliability
If albuvirtide compositions are formulated with specific buffer systems and pH control, then stability and purity are improved, but formulation complexity increases
Solution Approach 1:
The patent establishes specific parameter ranges for pH (acidic condition), buffer concentration, and excipient ratios that optimize composition reliability. By defining these parameters within optimal ranges rather than requiring exact values, the invention maintains reliability while reducing formulation complexity through flexible specification ranges.
Solution Approach 2:
The patent designs buffer systems that serve multiple functions: maintaining pH, providing stability, and facilitating manufacturing. This multi-functionality reduces the need for separate components, thereby improving reliability without proportionally increasing formulation complexity.
3Stability of the object's composition
If lyophilization is performed to improve storage stability, then purity is maintained, but manufacturing steps increase
Solution Approach 1:
The patent incorporates stabilizing excipients and buffer systems into the formulation before lyophilization. This preliminary action prepares the composition to withstand the lyophilization process and storage conditions, maintaining purity while reducing the need for additional post-lyophilization interventions that would decrease manufacturing efficiency.
Solution Approach 2:
The patent optimizes formulation parameters (pH, buffer concentration, excipient ratios) specifically for lyophilization compatibility. By adjusting these parameters in advance, the invention enables stable storage while minimizing the complexity of the lyophilization process itself, thus protecting productivity.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A liquid compositions and stable lyophilized compositions comprising albuvirtide, an HIV-1 fusion inhibitor. The present invention also provides the manufacturing process thereof and use of these compositions for the prevention, treatment or prophylaxis of diseases caused by HIV.